We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+3.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.91B
AUM Growth
+$61.2M
Cap. Flow
+$64.4M
Cap. Flow %
2.22%
Top 10 Hldgs %
30.43%
Holding
226
New
26
Increased
31
Reduced
48
Closed
30

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$41M
2
ABT icon
Abbott
ABT
+$37M
3
MRNA icon
Moderna
MRNA
+$32.5M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$29.2M
5
GILD icon
Gilead Sciences
GILD
+$26.5M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$60.5M
2
BDX icon
Becton Dickinson
BDX
+$22.1M
3
HUM icon
Humana
HUM
+$18.1M
4
TECH icon
Bio-Techne
TECH
+$16.1M
5
NVCR icon
NovoCure
NVCR
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 95.75%
2 Real Estate 2.99%
3 Industrials 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DXCM icon
26
DexCom
DXCM
$31.5B
$26.8M 0.92%
298,572
– –
RMD icon
27
ResMed
RMD
$30.6B
$25.7M 0.88%
132,344
– –
PFE icon
28
Pfizer
PFE
$143B
$25.6M 0.88%
705,259
– –
LH icon
29
Labcorp
LH
$25B
$25.4M 0.87%
115,911
+40,713
+54% +$8.17M
EXEL icon
30
Exelixis
EXEL
$13.3B
$24.9M 0.86%
1,100,920
-155,600
-12% -$3.51M
MCK icon
31
McKesson
MCK
$100B
$24.6M 0.85%
125,948
-4,500
-3% -$821K
GH icon
32
Guardant Health
GH
$21.7B
$24.2M 0.83%
158,727
+40,875
+35% +$6.18M
STE icon
33
Steris
STE
$22.3B
$24.1M 0.83%
126,779
– –
XRAY icon
34
Dentsply Sirona
XRAY
$2.68B
$22.4M 0.77%
351,427
-14,500
-4% -$841K
EXAS
35
DELISTED
Exact Sciences
EXAS
$22M 0.76%
167,302
+103,800
+163% +$14.2M
ALNY icon
36
Alnylam Pharmaceuticals
ALNY
$27.5B
$21.9M 0.75%
154,902
-19,992
-11% -$3.01M
NBIX icon
37
Neurocrine Biosciences
NBIX
$16.8B
$20.7M 0.71%
212,891
-81,343
-28% -$8.53M
SYNH
38
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$20.7M 0.71%
272,647
+77,511
+40% +$5.84M
EW icon
39
Edwards Lifesciences
EW
$49.6B
$20M 0.69%
238,755
-26,200
-10% -$2.21M
NVAX icon
40
Novavax
NVAX
$1.2B
$19.1M 0.66%
105,176
+28,591
+37% +$5.7M
ALLK
41
DELISTED
Allakos
ALLK
$18.8M 0.65%
163,645
+32,708
+25% +$4.13M
CRSP icon
42
CRISPR Therapeutics
CRSP
$4.73B
$18.4M 0.63%
150,958
+74,736
+98% +$11.3M
ARGX icon
43
argenx
ARGX
$53.4B
$17.7M 0.61%
64,344
+2,657
+4% +$840K
AZN icon
44
AstraZeneca
AZN
$263B
$17.1M 0.59%
172,167
– –
IDXX icon
45
Idexx Laboratories
IDXX
$44.1B
$17M 0.59%
34,814
– –
ALXN
46
DELISTED
Alexion Pharmaceuticals
ALXN
$16.9M 0.58%
110,693
-391,249
-78% -$60.5M
CVS icon
47
CVS Health
CVS
$133B
$16.6M 0.57%
219,995
– –
IOVA icon
48
Iovance Biotherapeutics
IOVA
$1.82B
$16.5M 0.57%
520,595
+249,522
+92% +$10.3M
PRAH
49
DELISTED
PRA Health Sciences, Inc.
PRAH
$15.9M 0.55%
103,943
-71,895
-41% -$9.76M
ISRG icon
50
Intuitive Surgical
ISRG
$127B
$15.7M 0.54%
63,888
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Tekla Capital Management held 226 positions worth $2.91B, up 2.1% from $2.85B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Tekla Capital Management's Q1 2021 filing shows 26 new, 31 increased, 48 reduced and 30 closed positions. Its largest new stake was Universal Health Services: 71,323 shares worth $9.51M. The largest sale was Alexion Pharmaceuticals, an estimated $60.5M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Real Estate and Industrials.

  • Tekla Capital Management's largest Q1 2021 buy was Universal Health Services: 71,323 shares worth $9.51M.
  • Tekla Capital Management added most to Elevance Health in Q1 2021, an estimated $41M increase.
  • Tekla Capital Management's biggest Q1 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $60.5M.
  • Tekla Capital Management fully exited NovoCure in Q1 2021, selling an estimated $15.2M.
  • Tekla Capital Management's ten largest holdings make up 30% of its $2.91B portfolio in Q1 2021.
  • Tekla Capital Management opened 26 new positions and closed 30 in Q1 2021.
  • Tekla Capital Management's portfolio value rose 2.1% quarter-over-quarter to $2.91B.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.